Press Releases

10.09.2016

First Positive Phase 3 Results In Adjuvant Setting For Renal Cell Carcinoma Show SUTENT® (sunitinib) Extended Disease Free Survival After Surgical Removal

10.09.2016

Pfizer Presents Promising New Immunotherapy Combination Data With INLYTA® (axitinib) In Advanced Renal Cell Carcinoma (RCC)

10.06.2016

ICU Medical Inc. To Acquire The Hospira Infusion Systems Business From Pfizer Inc. For $1 Billion In Cash And Stock

09.28.2016

iTeos Announces Initiation of Phase 1 Clinical Trial of IDO1 inhibitor

09.28.2016

Pfizer Completes Acquisition of Medivation

09.28.2016

Pfizer to Showcase Progress of Broad-Based Oncology Portfolio at European Society for Medical Oncology (ESMO) 2016 Congress

09.26.2016

Pfizer Decides Remaining One Company Best Positions Company To Maximize Future Value Creation

09.23.2016

Pfizer Announces Expiration of HSR Waiting Period For Proposed Acquisition of Medivation

09.22.2016

Pfizer Declares 30-Cent Fourth-Quarter 2016 Dividend

09.20.2016

Pfizer Invites Public To View And Listen To Webcast Of November 1 Conference Call With Analysts

09.16.2016

Pfizer Announces Positive Top-Line Results from REFLECTIONS B537-02 Study for PF-06438179 (infliximab-Pfizer) a Potential Biosimilar to Remicade® (infliximab)

09.16.2016

Pfizer Receives Positive CHMP Opinion For IBRANCE® (palbociclib) In Combination With Endocrine Therapy For The Treatment Of HR+/HER2- Metastatic Breast Cancer In Europe